Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
18 pending office actions • 18 art units • 18 examiners • 0 of 18 (0%) have an AI response strategy ready • 31 patents granted in the last 365 days
Academia Sinica has 18 pending office actions in Biotechnology & Pharmaceuticals. Each of the 18 matters is associated with a distinct examiner and a distinct art unit, indicating that the portfolio spans a wide range of examination assignments rather than a recurring examiner or unit.
PACKARD, BENJAMIN J is the busiest examiner, with 1 pending matter. Because no examiner accounts for more than that figure, prosecution strategy should be organized at the application level, with separate review of the issues arising in each assignment.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (28%) |
| §103 only | 5 (28%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 6 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PACKARD, BENJAMIN J | 1 | 66.9% | +15.3% |
| PARK, EVELYN GRACE | 1 | 51.6% | +40.5% |
| JOHNSON, KARA D | 1 | 69.3% | +25.1% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
| KELLY-O'NEILL, YOLANDA LYNNETTE | 1 | 31.8% | +23.7% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| TURNER, FELICIA C | 1 | 26.2% | +30.2% |
| EDWARDS, LYDIA E | 1 | 60.1% | +6.0% |
| OSTWALT, ALEXIS ROSE | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | BROWN, MINDY G | 13d |
| 18286943 | BOTANICAL SUPPLEMENT AND METHOD FOR PREVENTING DISEASES, PROMOTING GROWTH AND SURVIVAL OF AN ANIMAL BY USING THE SAME | TURNER, FELICIA C | 21d |
| 18358320 | REACTION PLATFORM FOR ACCELERATED BIOCHEMICAL REACTION | EDWARDS, LYDIA E | 34d |
| 18864006 | LIPIDS, NANOPARTICLES COMPRISING THE SAME AND USES THEREOF | PACKARD, BENJAMIN J | — |
| 18854965 | Non-Invasive Blood Glucose Prediction by Deduction Learning System | PARK, EVELYN GRACE | — |
| 18686862 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | HOWARD, ZACHARY C | — |
| 18429813 | CONVERSION OF BETA-HYDROXY CARBONYL SPECIES AND PREPARATION OF AMINO ALCOHOL PRECURSOR USING BIFUNCTIONAL CATALYSTS DERIVED FROM LAYERED DOUBLE HYDROXIDES | KELLY-O'NEILL, YOLANDA LYNNETTE | — |
| 18572564 | COMBINED CANCER THERAPY WITH AN EPITHELIAL CELL ADHESION MOLECULE (EPCAM) INHIBITOR AND A WNT INHIBITOR | PRIEST, JESSICA MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286943 | BOTANICAL SUPPLEMENT AND METHOD FOR PREVENTING DISEASES, PROMOTING GROWTH AND SURVIVAL OF AN ANIMAL BY USING THE SAME | TURNER, FELICIA C | 21d |
| 18864006 | LIPIDS, NANOPARTICLES COMPRISING THE SAME AND USES THEREOF | PACKARD, BENJAMIN J | — |
| 18854965 | Non-Invasive Blood Glucose Prediction by Deduction Learning System | PARK, EVELYN GRACE | — |
| 18697799 | CELL CULTURE PLATFORMS, METHODS AND USES THEREOF | JOHNSON, KARA D | — |
| 18689852 | COMPOUNDS AND THEIR USES FOR TREATING NEURODEGENERATIVE DISEASE | MOU, LIYUAN | — |
| 18686862 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | HOWARD, ZACHARY C | — |
| 18429813 | CONVERSION OF BETA-HYDROXY CARBONYL SPECIES AND PREPARATION OF AMINO ALCOHOL PRECURSOR USING BIFUNCTIONAL CATALYSTS DERIVED FROM LAYERED DOUBLE HYDROXIDES | KELLY-O'NEILL, YOLANDA LYNNETTE | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 3791 | 1 |
| 1632 | 1 |
| 1628 | 1 |
| 1674 | 1 |
| 1692 | 1 |
| 1642 | 1 |
| 1793 | 1 |
| 1796 | 1 |
| 1789 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864006 | LIPIDS, NANOPARTICLES COMPRISING THE SAME AND USES THEREOF | PACKARD, BENJAMIN J | 1612 | §102§103 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18854965 | Non-Invasive Blood Glucose Prediction by Deduction Learning System | PARK, EVELYN GRACE | 3791 | §101§102§112 | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18697799 | CELL CULTURE PLATFORMS, METHODS AND USES THEREOF | JOHNSON, KARA D | 1632 | §103§112DP | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18689852 | COMPOUNDS AND THEIR USES FOR TREATING NEURODEGENERATIVE DISEASE | MOU, LIYUAN | 1628 | §103 | Final Rejection | — | Pending | Mar 06, 2024 |
| 18686862 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | HOWARD, ZACHARY C | 1674 | §102§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18429813 | CONVERSION OF BETA-HYDROXY CARBONYL SPECIES AND PREPARATION OF AMINO ALCOHOL PRECURSOR USING BIFUNCTIONAL CATALYSTS DERIVED FROM LAYERED DOUBLE HYDROXIDES | KELLY-O'NEILL, YOLANDA LYNNETTE | 1692 | §103§112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18572564 | COMBINED CANCER THERAPY WITH AN EPITHELIAL CELL ADHESION MOLECULE (EPCAM) INHIBITOR AND A WNT INHIBITOR | PRIEST, JESSICA MARIE | 1642 | §103§112Other | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18286943 | BOTANICAL SUPPLEMENT AND METHOD FOR PREVENTING DISEASES, PROMOTING GROWTH AND SURVIVAL OF AN ANIMAL BY USING THE SAME | TURNER, FELICIA C | 1793 | §103 | Non-Final OA | 21d | Pending | Oct 13, 2023 |
| 18358320 | REACTION PLATFORM FOR ACCELERATED BIOCHEMICAL REACTION | EDWARDS, LYDIA E | 1796 | §102§103 | Final Rejection | 34d | Pending | Jul 25, 2023 |
| 18222627 | ELECTRODE AND LITHIUM-ION BATTERY COMPRISING THE SAME | OSTWALT, ALEXIS ROSE | 1789 | §102§103 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18267996 | CELL CULTURE SYSTEMS, METHODS AND USES THEREOF | GONZALES, JOSEPHINE MARIA | 1638 | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18266882 | ANTAGONIST OF INTERLEUKIN-17B RECEPTOR (IL-17RB) AND USE THEREOF | BRADLEY, CHRISTINA | 1654 | §101§102§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
| 18116952 | COMPOSITION AND METHOD FOR MODULATING FIBROBLAST GROWTH FACTOR RECEPTOR 3 ACTIVATION | RZECZYCKI, PHILLIP MATTHEW | 1625 | §101§102 | Final Rejection | — | Pending | Mar 03, 2023 |
| 17925119 | FLOW CHEMISTRY SYSTEM AND METHOD FOR CARBOHYDRATE ANALYSIS | HUANG, MICKEY NMN | 1758 | §103 | Final Rejection | 49d overdue | Pending | Nov 14, 2022 |
| 17946651 | METAL OXIDES-SILICA COMPOSITE AND METHOD FOR PREPARING THE SAME | PATEL, SMITA S | 1732 | §103 | Non-Final OA | — | Pending | Sep 16, 2022 |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | BROWN, MINDY G | 1681 | §101§112Other | Non-Final OA | 13d | Pending | Jun 14, 2022 |
| 17781412 | Oligopeptide, Testing Kit Thereof And Medical Composition Thereof | GAO, ASHLEY HARTMAN | 1678 | §112 | Final Rejection | — | Pending | Jun 01, 2022 |
| 17630929 | METHODS OF TREATING POMPE DISEASE | CHONG, YONG SOO | 1623 | §103 | Non-Final OA | — | Pending | Jan 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcademia Sinica has 18 pending office actions as of October 2026, spread across 18 art units and 18 examiners.
Benjamin J Packard has the most, with 1 of Academia Sinica's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
